Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis. 1983

A Tourkantonis, and P Nicolaidis

The pharmacokinetics of ceftazidime were studied in 12 patients during peritoneal dialysis. In five patients given 1 g iv the mean serum levels (mg/l) at 0.25, 2 and 12 h after starting peritoneal dialysis were 50.6 +/- 11.2, 35.6 +/- 3.7 and 22.7 +/- 7.9, respectively. The mean ceftazidime peak level was 13.2 +/- 5.5 mg/l in peritoneal effluent, approximately 3 h after start of dialysis. The peritoneal clearance was 9 ml/min and the mean half-life during and after peritoneal dialysis was 8.7 +/- 3.1 h and 26.9 +/- 11 h, respectively. In four patients, 1 g ceftazidime was given via an intraperitoneal catheter. The mean serum levels (mg/l) at 0.25, 2 and 8 h were 14.2 +/- 3.1, 40.0 +/- 13.0 and 32.5 +/- 6.4 respectively. In three patients given ceftazidime 200 mg, in 21 dialysate treatments each with 12 cycles, mean serum levels increased from 1.3 +/- 1.5 mg/l at 1 h to 25.3 +/- 3.1 mg/l at 12 h. Mean levels in the dialysis effluent were 47.2 +/- 14.3 mg/l and the mean percentage of the dose recovered in the effluent was 47.1%. We concluded that (1) 1 g ceftazidime as an iv bolus maintained serum and peritoneal effluent levels adequate to treat patients; (2) its peritoneal absorption produced high ceftazidime levels in serum; (3) in infected patients undergoing peritoneal dialysis ceftazidime may be given either by the intravenous or intraperitoneal route.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007700 Kinetics The rate dynamics in chemical or physical systems.
D010530 Peritoneal Dialysis Dialysis fluid being introduced into and removed from the peritoneal cavity as either a continuous or an intermittent procedure. Dialyses, Peritoneal,Dialysis, Peritoneal,Peritoneal Dialyses
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Tourkantonis, and P Nicolaidis
December 1983, Antimicrobial agents and chemotherapy,
A Tourkantonis, and P Nicolaidis
September 2023, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
A Tourkantonis, and P Nicolaidis
December 1982, International journal of clinical pharmacology, therapy, and toxicology,
A Tourkantonis, and P Nicolaidis
July 1992, Antimicrobial agents and chemotherapy,
A Tourkantonis, and P Nicolaidis
January 2003, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
A Tourkantonis, and P Nicolaidis
September 1976, Antimicrobial agents and chemotherapy,
A Tourkantonis, and P Nicolaidis
April 1981, Antimicrobial agents and chemotherapy,
A Tourkantonis, and P Nicolaidis
September 2023, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
A Tourkantonis, and P Nicolaidis
April 1988, The Japanese journal of antibiotics,
Copied contents to your clipboard!